DOI: 10.36347/sasjs.2021.v07i10.014

Pages: 582-589

Background: Malignant pancreatic cancer has a high death rate, and it is difficult to treat because of the excruciating agony it causes. Opioids and adjuvants are commonly used to alleviate severe stomach pain. Objectives: CPB is a type of neural therapy treatment. Limited and inconsistent research has been done on the impact of QoL on patients. We hoped to find a solution to this problem with this investigation. Materials and Methods: Multicenter non-randomized quasi-experimental prospective study has been conducted in Rajshahi Medical College Hospital and tertiary care Hospital Rajshahi, Bangladesh. From January 2019 until July 2021.We studied a total of 16 patients with severe abdominal pain who had failed to react to combination systemic analgesic treatment or who had adverse effects that made it impossible to continue with the current dosage. A 35-day follow-up study looked at the effectiveness of CPB as a palliative analgesic. The VAS questionnaire was used to see if pain intensity could be altered as a primary result. The SF-36 questionnaire enhanced QoL secondary outcomes. We closely monitored the pain medications for any undesirable side effects. Results: Patients' VAS pain scores dropped significantly (P=0.002) after CPB, and their need for opiates dropped as well. When the extent of the impact is taken into consideration, their QoL scores also increased (P<0.001). During the research period, no side effects associated with CPB were found. There were also no negative medication responses. Conclusion: Our findings provide early evidence that CPB may be beneficial in individuals with advanced pancreatic cancer who are also receiving conventional pain medication. CPB appears to enhance QoL in these individuals at least 5 weeks after the Intervention, according to this research.